Cisplatin

This classification denotes a radiosensitizing agent and platinum compound with the molecular formula 2Cl.Pt.2H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q20Q21Q62J, chemically known as platinum(ii), diamminedichloro-, trans- but more generally known as cisplatin, which bears US NIH Compound Identifier 2767. European Medicines Agency schedules Cisplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07483MIG. The term CISPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules cisplatin in its Anatomical Therapeutic Chemical (ATC) Classification. CISPLATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule cisplatin under HS 28439000 and SITC 52432. SMILES: N.N.[Cl-].[Cl-].[Pt+2].